Search results

Jump to navigation Jump to search

Page title matches

Page text matches

  • ...anized. If only the constant region is modified they are called [[Chimeric monoclonal antibody|chimeric]]." <ref>{{MeSH}}</ref> * [[Humanized monoclonal antibody]]. INN names end in -zumab
    787 bytes (103 words) - 08:56, 26 April 2014
  • A '''monoclonal antibody''' is an immune substance "produced by clones of cells such as those isolat * [[Human monoclonal antibody]]. INN names end in -umab. Example is [[olaratumab]].
    2 KB (244 words) - 09:00, 26 April 2014
  • ...ounds (e.g., aurothioglucose), [[antimalarial]]s, [[penicillamine]], and [[monoclonal antibody|monoclonal antibodies]] against [[tumor necrosis factor-alpha]] and other i
    422 bytes (46 words) - 19:00, 18 September 2010
  • A [[monoclonal antibody]] used as an [[antineoplastic agent]]
    97 bytes (11 words) - 12:24, 17 July 2010
  • | pagename = Humanized monoclonal antibody | abc = Humanized monoclonal antibody
    851 bytes (69 words) - 08:45, 26 April 2014
  • A [[monoclonal antibody]] useful in treatment of [[HER2]]-positive metastatic [[breast cancer]]
    131 bytes (15 words) - 07:56, 5 February 2009
  • <noinclude>{{Subpages}}</noinclude>An antineoplastic agent that uses a [[monoclonal antibody]] to deliver radioisotopes to cancer cells
    135 bytes (17 words) - 00:53, 1 November 2010
  • Antibodies include [[monoclonal antibody|monoclonal antibodies]].
    412 bytes (53 words) - 08:33, 26 April 2014
  • A [[antineoplastic agent]], of the [[monoclonal antibody]] class, directed against the CDw52 antigen expressed by [[lymphocyte]]s
    165 bytes (20 words) - 09:14, 5 February 2009
  • Chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of B cell
    204 bytes (30 words) - 10:52, 8 September 2009
  • {{r|Monoclonal antibody}}
    381 bytes (44 words) - 10:34, 18 October 2008
  • {{r|Monoclonal antibody}}
    196 bytes (22 words) - 16:49, 1 August 2010
  • [[Cetuximab]] (IMC-C225) is a recombinant, human/mouse chimeric [[monoclonal antibody]] that binds to EGFR and may treat head and neck cancers, [[colorectal canc ...&id=19339720 | doi=10.1056/NEJMoa0805019 }} </ref> Panitumumab is also a [[monoclonal antibody]] that binds to EGFR and may treat [[colorectal cancer]].
    1 KB (208 words) - 07:56, 1 May 2010
  • | pagename = Monoclonal antibody
    2 KB (230 words) - 09:38, 5 February 2009
  • ...''trastuzumab''' (pronounced tras too' zoo mab), '''Herceptin''' ®, is a [[monoclonal antibody]] against the [[ErbB-2 receptor]] (HER2) that lengthens remission time in m
    707 bytes (88 words) - 11:35, 23 March 2010
  • {{r|Catumaxomab}} Is a monoclonal antibody against CD3 (Entrez protein)and EpCAM (Entrez protein). "Extracorporeal PBM {{r|Bevacizumab}}is an "anti-VEGF (Entrez protein) monoclonal antibody consisting of humanized murine antibody with antigen-binding, complementary
    4 KB (467 words) - 00:17, 6 February 2009
  • {{r|Anti-TNF monoclonal antibody||**}}
    1 KB (149 words) - 03:19, 28 December 2010
  • Auto-populated based on [[Special:WhatLinksHere/Monoclonal antibody]]. Needs checking by a human.
    640 bytes (83 words) - 18:38, 11 January 2010
  • [[Monoclonal antibody|monoclonal antibodies]] targeting [[tumor necrosis factor]] are the most re
    2 KB (190 words) - 13:54, 25 June 2010
  • The [[monoclonal antibody]] [[palivizumab]], three to five monthly [[intramuscular injection]]s, can
    932 bytes (122 words) - 06:13, 23 August 2010
  • {{r|Monoclonal antibody}}
    958 bytes (113 words) - 15:14, 18 January 2010
  • {{r|Monoclonal antibody}}
    1 KB (141 words) - 22:00, 30 July 2010
  • * [[Cetuximab]] (IMC-C225) is a recombinant, human/mouse chimeric [[monoclonal antibody]] that binds to [[epidermal growth factor receptor]] (ErbB1, EGFR) and may * [[Catumaxomab]]. Is a monoclonal antibody against CD3 ([http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein&term=NM_0
    10 KB (1,356 words) - 06:07, 5 April 2024
  • {{r|Monoclonal antibody}}
    2 KB (219 words) - 21:43, 11 January 2010
  • [[Antitoxin]]s, drugs using [[monoclonal antibody|monoclonal antibodies]], etc., which directly attack or neutralize the path ...directly counteract the effects of the pathogen, as do [[antitoxin]]s or [[monoclonal antibody|monoclonal antibodies]] that kill organisms, passively add immune defensive
    7 KB (1,004 words) - 10:12, 30 May 2009
  • }}</ref> [[monoclonal antibody]] consisting of humanized [[murine]] antibody with antigen-binding, complem
    3 KB (376 words) - 14:53, 17 July 2010
  • The leading edge of approved treatment, however, are specific [[monoclonal antibody|monoclonal antibodies]].
    4 KB (541 words) - 14:37, 31 July 2010
  • [[Trastuzumab]] is a [[monoclonal antibody]] against the ErbB-2 receptor that lengthens remission time in metastatic [
    2 KB (308 words) - 06:03, 16 July 2010
  • * [[Infliximab]] (Remicade) (pronounced in flix' i mab) is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.<ref>{{CZMed|Inflixima
    8 KB (1,138 words) - 02:03, 4 November 2010
  • * [[Adalimumab]] is a [[monoclonal antibody]].
    2 KB (306 words) - 17:09, 26 May 2023
  • ...opurine]] and [[azathioprine]], as well as [[methotrexate]]. Recently, a [[monoclonal antibody]] against [[tumor necrosis factor-alpha]], [[infliximab]], has come into us
    4 KB (547 words) - 16:34, 2 August 2010
  • [[Rituximab]], a [[monoclonal antibody]], was found to be safe by a [[systematic review]] of 21 studies, although
    3 KB (477 words) - 12:55, 8 September 2020
  • 3 KB (445 words) - 15:57, 28 June 2010
  • ...s of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]] [[abciximab]] and the small-molecule agents [[tirofiban]] and [[eptifiba
    4 KB (543 words) - 01:43, 8 May 2013
  • ...he person's blood. Any p24 protein in the person's blood will stick to the monoclonal antibody and enzyme-linked antibody to the monoclonal antibodies to p24 causes a col
    26 KB (3,990 words) - 13:22, 2 February 2023
  • 5 KB (667 words) - 11:08, 30 September 2011
  • ...d for [[non-Hodgkin’s lymphom]]a. <sup>90</sup>Y-Ibritumomab Tiuxetan, a [[monoclonal antibody]], is currently unavailable in generic form due to its patented brand name, ...ation with radioactive <sup>90</sup>[[Yttrium]]. Ibritumomab Tiuxetan, the monoclonal antibody, is therefore coupled with a radioactively [[cytotoxic]] agent capable of d
    11 KB (1,563 words) - 03:38, 7 October 2013
  • ...rpr|molecular genetics}} {{rpr|molecular phylogeny}} {{rpr|mollusc}} {{rpr|monoclonal antibody}} {{rpr|morphogenesis}} {{rpr|morphometrics}} {{rpr|morula}} {{rpr|MRI}} {{
    11 KB (1,401 words) - 06:54, 22 February 2010
  • ...e development and control of the [[immune system]] and the production of [[monoclonal antibody|monoclonal antibodies]]
    21 KB (2,676 words) - 09:02, 1 March 2024
  • ...rpl|molecular genetics}} {{rpl|molecular phylogeny}} {{rpl|mollusc}} {{rpl|monoclonal antibody}} {{rpl|morphogenesis}} {{rpl|morphometrics}} {{rpl|morula}} {{rpl|MRI}} {{
    12 KB (1,430 words) - 12:21, 1 July 2009
  • *[[Monoclonal antibody/Definition]]
    15 KB (1,521 words) - 09:02, 2 March 2024
  • ...ion]] - [[molecular genetics]] - [[molecular phylogeny]] - [[mollusc]] - [[monoclonal antibody]] - [[morphogenesis]] - [[morphometrics]] - [[morula]] - [[MRI]] - [[Muller
    17 KB (2,197 words) - 17:09, 21 March 2024
  • 38 KB (5,208 words) - 09:02, 1 March 2024
  • ...ontrolled trial]], the [[relative risk ratio]] of adjunct treatment with [[monoclonal antibody|monoclonal antibodies]] against C. difficile toxins, as compared to [[place
    46 KB (6,252 words) - 17:10, 31 October 2013
  • ...fit for some patients but generally do not slow disease progression. Newer monoclonal antibody treatments against beta-amyloid protein, for example, the drug Leqembi, hav
    16 KB (2,171 words) - 08:34, 6 March 2024
  • ...ions measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus ''J Clin Endocrin
    31 KB (4,537 words) - 09:57, 18 February 2011
  • The [[monoclonal antibody]] against [[interleukin]]-1 beta, [[canakinumab]], may help according to a
    24 KB (3,312 words) - 17:35, 10 February 2024
  • ...ng allows plants to be modified to express proteins such as a therapeutic monoclonal antibody used in the treatment of arthritis, vaccine proteins, or for treatment of d
    23 KB (3,331 words) - 21:51, 3 March 2010
  • Cetuximab, an I<sub>g</sub>G1 chimeric monoclonal antibody against epidermal growth factor receptor, may help according to a [[randomi
    31 KB (4,194 words) - 13:28, 10 February 2023
  • ...refractory cases. TNF-a is a cachexin or cachectin. Its inhibitors, all [[monoclonal antibody|monoclonal antibodies]]; they are immunosuppressive with attendant risks. T
    48 KB (6,593 words) - 11:52, 2 February 2023
  • ...m, and cerebellum regions. Using an immunohistochemical analysis for OX-42 monoclonal antibody, they found a marked reduction of microglial activation in ribavirin-treate
    28 KB (4,083 words) - 03:50, 14 February 2010
  • ...e patients may be candidates for the drug [[trastuzumab]] (Herceptin), a [[monoclonal antibody]] that targets this protein. [[Trastuzumab]] may be used both in the posts ...presses an over-abundance of the [[erbB-2 receptor]] (HER2, HER2/neu), a [[monoclonal antibody]] known as [[trastuzumab]] (Herceptin ®) is used to block the activity of
    101 KB (14,716 words) - 09:04, 5 April 2024
  • Denosumab is a humanized monoclonal antibody that inhibits osteoclasts.<ref name="pmid16495394">{{cite journal |author=M
    49 KB (6,739 words) - 13:28, 10 February 2023
  • ...tural substances, or might, as soon as some folate antagonist or TNF-alpha monoclonal antibody becomes available, do provings on it and add it to their lists of remedies?
    41 KB (6,670 words) - 15:35, 24 October 2009
  • ...action of either an individualized genetic treatment using a customized [[monoclonal antibody]], or accept the hypotheses of potentiation of water, I will not accept the
    111 KB (18,002 words) - 15:52, 4 January 2009
  • ...he experimental group may have received a different, personalized modified monoclonal antibody. If there are better outcomes in the experimental group, the trial confirms ...that there was commercial justification to develop a specific neutralizing monoclonal antibody.
    191 KB (30,468 words) - 15:50, 4 January 2009
  • ...t first to look for the genetic pattern, and, perhaps try, ''in vitro'', a monoclonal antibody or other agent tailored for the individual problem. Only if the circulating
    83 KB (13,126 words) - 15:51, 4 January 2009